Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders

by Barry101 | Oct 22, 2018 | Press Release

ORLANDO, Fla., Oct. 22, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also...

Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma

by Barry101 | Oct 10, 2018 | Press Release

New Agreement Expands Existing Preclinical CollaborationsOCALA, Fla., Oct. 10, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in...

Hemispherx Biopharma Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center to Study Ampligen in Combination with Checkpoint Inhibitors in a Phase IIa Study in Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma

by Barry101 | Oct 10, 2018 | Press Release

New Agreement Expands Existing Preclinical CollaborationsOCALA, Fla., Oct. 10, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announces the signing of a clinical trial agreement with Roswell Park Comprehensive Cancer Center to evaluate Ampligen in...

Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe

by Barry101 | Sep 18, 2018 | Press Release

Ampligen supply will support product launch in Argentina, Expanded Access Programs for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the United States and Europe and pancreatic cancer in the Netherlands, and upcoming U.S. based Phase I/II...

Hemispherx to Distribute Second Lot of Ampligen® for use in Multiple Indications in Argentina, the United States and Europe

by Barry101 | Sep 18, 2018 | Press Release

Ampligen supply will support product launch in Argentina, Expanded Access Programs for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the United States and Europe and pancreatic cancer in the Netherlands, and upcoming U.S. based Phase I/II...

Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order

by Barry101 | Aug 28, 2018 | Press Release

ORLANDO, Fla., Aug. 28, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that the new Ampligen batch manufactured earlier this year is now released  for patients’ use in the pancreatic cancer Early Access Program (EAP) in the...